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Abstract
Background: Retinal ischemia results in neuronal degeneration and contributes to the pathogenesis of multiple
blinding diseases. Recently, the fumaric acid ester dimethyl fumarate (DMF) has been FDA-approved for the
treatment of multiple sclerosis, based on its neuroprotective and anti-inflammatory effects. Its potential role as a
neuroprotective agent for retinal diseases has received little attention. In addition, DMF’s mode of action remains
elusive, although studies have suggested nuclear factor erythroid 2-related factor 2 (Nrf2) activation as an important
mechanism. Here we investigated the neuroprotective role of monomethyl fumarate (MMF), the biologically active
metabolite of DMF, in retinal ischemia-reperfusion (I/R) injury, and examined the role of Nrf2 in mediating MMF action.
Methods: Wild-type C57BL/6J and Nrf2 knockout (KO) mice were subjected to 90 min of retinal ischemia followed
by reperfusion. Mice received daily intraperitoneal injection of MMF. Inflammatory gene expression was measured
using quantitative reverse transcription PCR (qRT-PCR) at 48 h after I/R injury. Seven days after I/R, qRT-PCR for Nrf2
target gene expression, immunostaining for Müller cell gliosis and cell loss in the ganglion cell layer (GCL), and
electroretinography for retinal function were performed.
Results: The results of this study confirmed that MMF reduces retinal neurodegeneration in an Nrf2-dependent
manner. MMF treatment significantly increased the expression of Nrf2-regulated antioxidative genes, suppressed
inflammatory gene expression, reduced Müller cell gliosis, decreased neuronal cell loss in the GCL, and improved
retinal function measured by electroretinogram (ERG) after retinal I/R injury in wild-type mice. Importantly, these
MMF-mediated beneficial effects were not observed in Nrf2 KO mice.
Conclusions: These results indicate that fumaric acid esters (FAEs) exert a neuronal protective function in the
retinal I/R model and further validate Nrf2 modulation as a major mode of action of FAEs. This suggests that
DMF and FAEs could be a potential therapeutic agent for activation of the Nrf2 pathway in retinal and possibly
systemic diseases.
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Background
Retinal ischemia contributes to visual impairment and
is critically involved in the pathogenesis of several dis-
eases, including acute angle-closure glaucoma, retinal
vascular occlusions, age-related macular degeneration,
and diabetic retinopathy [1, 2]. Currently, there is no
therapy for retinal ischemia.
Among the most widely used models to study the
molecular mechanisms and test potential therapeutic
approaches for retinal ischemia are rodent models of
ischemia-reperfusion (I/R), in which intraocular pres-
sure is acutely elevated above the systolic pressure for a
specified period of time followed by reperfusion. Reperfu-
sion of the retina after ischemia results in oxidative stress
that is marked by the production of reactive oxygen spe-
cies (ROS) and subsequent inflammatory responses [3–5],
resulting in neurodegeneration manifested by the loss of* Correspondence: eduh@jhmi.edu
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retinal ganglion cells (RGC) and a significant reduction of
b wave amplitude in the electroretinogram (ERG) [6, 7].
Recently, it has been shown that fumaric acid esters
(FAEs) enhance survival of various central nervous sys-
tem (CNS) cell types in response to oxidative insults in
vitro [8–12], improve outcomes in animal models of
Huntington’s disease and experimental autoimmune en-
cephalomyelitis [8, 13], and activate the nuclear factor
erythroid 2-related factor 2 (Nrf2) pathway and upregu-
late Nrf2-dependent antioxidant genes and proteins in
the brain [8, 9]. This suggests that Nrf2 activation may
be an important pathway mediating the effects of FAEs.
Importantly, the fumaric acid ester dimethyl fumarate
(DMF; Tecfidera/BG-12) has recently been approved by
the FDA for the treatment of multiple sclerosis based
on its neuroprotective and anti-inflammatory effects.
Once ingested, DMF is rapidly and extensively metabo-
lized in the GI tract by esterases into monomethyl
fumarate (MMF), which is the biologically and pharma-
cologically active metabolite of DMF [14, 15]. Despite
numerous studies showing protective effects of FAEs in
CNS disease models [16, 17], little information is available
on therapeutic effects of FAEs on retinal conditions.
Nrf2 is a transcription factor known to play a major cyto-
protective role against endogenous and exogenous stresses
and serves as one of the most important cellular pathways
in protection against oxidative stress [18, 19]. Under nor-
mal physiological conditions, most Nrf2 are sequestered in
the cytoplasm through interactions with its inhibitor,
Keap1, which also directs Nrf2 toward ubiquitination and
subsequent proteosomal degradation. Upon exposure to
various endogenous or exogenous stress-inducing agents
such as reactive oxygen species, Nrf2 dissociates from
Keap1 and translocates to the nucleus, where it mediates
the activations of an array of cytoprotective and antioxidant
genes via binding to the antioxidant response element
[19]. This mode of regulation is particularly amenable
to pharmacological modulation, enabling Nrf2 activation by
multiple drugs known to induce the Nrf2 pathway [20].
Both DMF and MMF have been shown to activate the Nrf2
pathway [8, 9, 21]; however, the importance of Nrf2 activa-
tion in their therapeutic effects remains to be established.
Here we tested the hypothesis that MMF exerts neur-
onal protection in the retina after I/R injury via the
Nrf2 pathway. Our data show that MMF treatment in-
duces upregulation of Nrf2 target genes, suppresses in-
flammatory gene expression, mitigates reactive Müller
cell gliosis, inhibits I/R-induced neuronal cell loss, and
partially restores electrophysiological function of the
retina after I/R injury in an Nrf2-dependent manner.
Together, our findings suggest that FAEs are a promis-
ing neuroprotective agent for retinal I/R and might be
beneficial for other retinal and systemic conditions, es-
pecially those in which Nrf2 activation is desirable.
Methods
Animals
Animal studies were approved by the Institutional Animal
Care and Use Committee of the Johns Hopkins University
School of Medicine. All procedures involving animals
were conducted in accordance with the Association for
Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research. Nrf2
knockout (KO) mice backcrossed into C57BL/6 J [2, 22]
and wild-type C57BL/6 J mice (Jackson Laboratory) were
used for all experiments. The mice were maintained under
standard conditions on a 12-h light to dark cycle with ad
libitum access to food and water. The animals were ran-
domly assigned into each experimental group in equal
numbers. Due to attrition (death during I/R or ERG pro-
cedures, or formation of severe cataract after I/R) not all
groups contain the same number of animals.
Mouse model of retinal ischemia-reperfusion and
monomethyl fumarate treatment
Retinal ischemia was induced as described previously
[2]. Mice were anesthetized with a cocktail of 100 mg/kg
ketamine, 10 mg/kg xylazine, and 3 mg/kg acepromazine
via intraperitoneal (i.p.) injection. The anterior chamber
of one eye was cannulated with a 30-gauge needle at-
tached to a line infusing 0.9 % sterile saline. The intraoc-
ular pressure (IOP) was raised to 90 mmHg by elevating
the saline reservoir. The retina was monitored for
blanching, which indicates retina ischemia. After 90 min
of ischemia, the needle was withdrawn from the eye and
the IOP was restored. The untreated contralateral eye of
the same mouse was used as a control. Mice were
treated with intraperitoneal injections of 50 mg/kg of
MMF (dissolved in phosphate-buffered saline (PBS),
Sigma Aldrich, St. Louis, MO) or PBS at 2 days, 1 day,
and 0 day before I/R. After I/R, mice were treated daily
with MMF until sacrificed at designated time points.
The expression of antioxidant genes, Müller cell gliosis,
and neuronal cell death in the ganglion cell layer (GCL)
and ERG were all measured at 7 days to allow sufficient
time to develop I/R-induced deficiencies. However, the
inflammatory gene expression was measured at 48 h, as
I/R-induced upregulation of inflammatory gene expres-
sion peaks in the first 48 h.
Quantitative Reverse Transcription PCR
Total RNA from the retina was isolated using RNeasy
mini kit (Qiagen, Valencia, CA) with a DNase (Qiagen,
Valencia, CA) treatment. Single-stranded cDNA was
synthesized using MMLV Reverse Transcriptase (Invi-
trogen). Quantitative reverse transcription PCR (qRT-
PCR) was performed using the QuantiTect SYBR Green
PCR Kit (Qiagen) with the StepOnePlus real-time PCR
system (Applied Biosystems). The qRT-PCR primers
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used in this study to analyze the expression of Nrf2 tar-
get genes and inflammatory mediators are listed in
Table 1. The roles of each of these genes are explained
in Table S1 (Additional file 1: Table S1). The house-
keeping gene Cyclophilin A was used for normalization.
The fold difference between levels of transcripts was
calculated using the ΔΔCT method.
Immunohistochemistry
Following enucleation, eyes were immediately fixed in
10 % buffered formalin overnight at room temperature
(RT). The fixed eyes were dehydrated with a series of
ethanol washes, embedded in paraffin, and cross-
sectioned (5 μm). Sections were subjected to heat-
induced antigen retrieval in Target Retrieval Solution
(Dako, Carpinteria, CA). Slides were blocked in 5 %
goat serum in PBST (0.1 % Triton-X in PBS) for 1 h at
RT and then incubated with rabbit anti-glial fibrillary
acidic protein (GFAP) (1:1000) (Abcam, Cambridge,
MA) for 16 h at 4 °C. After washing, the sections were
incubated with goat anti-rabbit antibody (1:500) conju-
gated with Alexa fluor 488 (Life Technologies, Grand
Island, NY) for 1 h at RT. Sections were then cover-
slipped using Prolong Gold Antifade Mountant with
DAPI (Life Technologies, Grand Island, NY) for nuclear
staining. Retina cross-section images containing all retinal
layers were captured in a blinded manner using a confocal
microscope (Zeiss LSM 510, Carl Zeiss, Thornwood, NY)
with a ×20 objective lens. From each eye, three non-
overlapping fields from central- and mid-periphery, in-
cluding all layers of the retina, were used for analysis. For
each field, ten serial confocal images were taken at
1 μm intervals and then merged to produce well-
focused images with maximum signal. Quantitation of
immunostaining was performed as described previously
[23]. Briefly, images were converted to 8-bit in ImageJ
software (NIH), and an intensity threshold for
immunofluorescence was set so that only GFAP-positive
areas were highlighted. Results are expressed as the per-
centage of positive immunofluorescence area per field
of retina. Investigators were masked to the groups dur-
ing analysis.
Retina whole-mount immunostaining
In order to assess surviving neurons within the GCL,
retinal whole-mount staining was performed as previ-
ously described [24]. Briefly, mouse eyes were enucleated
and fixed in 4 % paraformaldehyde (PFA) in PBS for
30 min at RT. The corneas and lenses were then re-
moved, and eyecups were fixed in 4 % PFA for an add-
itional 10 min before each retina was carefully dissected
from its eyecup. Retinas were incubated for 1 hour at
RT in a blocking solution containing 10 % normal goat
serum in PBST (0.3 % Triton-X in PBS), followed by la-
beling with anti-NeuN antibody (1:600, Millipore, Biller-
ica, MA) at 4 °C overnight. The retinas were then
extensively washed in PBST for 3 h with changes of
PBST every 30 min, followed by labeling with anti-
mouse IgG conjugated with Alexa Fluor 488 antibody
(Invitrogen, Carlsbad, CA) at 4 °C overnight. After wash-
ing with PBST, the retinas were flat-mounted on slides
in Fluoromount-G (Electron Microscopy Sciences, Hat-
field, PA). The survival of neuronal cells in ganglion cell
layer was analyzed as previously described [25]. Retina
whole-mount images were taken using a confocal micro-
scope (Zeiss LSM 510, Carl Zeiss, Thornwood, NY) with
a ×20 objective lens. Eight random fields in the retinal
mid-periphery were selected from each eye. For each
field, five serial z-stacked images at 1-μm intervals in
ganglion cell layer were taken and then merged to pro-
duce well-focused images with maximum signal. NeuN-
positive cells in GCL were manually counted in a
masked fashion using the Count Tool in Adobe Photo-
shop CS6 (Adobe Systems Inc., San Jose, CA).
Table 1 qRT-PCR primers used in this study











Cyclophilin A GAGCTGTTTGCAGACAAAGTT CCCTGGCACATGAATCCTGG
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Flash scotopic electroretinogram
All procedures were done under dim red light. Before elec-
troretinogram (ERG) analysis, mice were dark adapted
overnight. Mice were anesthetized with ketamine (100 mg/
kg) and xylazine (10 mg/kg), and the pupils were dilated
with a drop of 1 % Tropicamide on the corneal surface
before they were placed in the Bigshot™ LED Ganzfeld
stimulator (LKC Technologies, Gaithersburg, MD) on the
electroretinogram system (UTAS Visual Diagnostic Sys-
tem, LKC Technologies, Gaithersburg, MD). Flash ERG
was measured using gold wire corneal electrodes, with a
forehead reference electrode and a ground electrode near
the tail. Electrodes were connected to the Universal DC
Biomedical Amplifier (UBS-4204, LKC Technologies,
Gaithersburg, MD), and bands were filtered from 0.3 to
500 Hz. Data were recorded and analyzed using EM for
Windows (Ver. 9.0.0, LKC Technologies, Gaithersburg,
MD) in a blinded manner. Scotopic ERG waveforms
were measured at flash intensities of −30, −20, −10, 0, 5, 10,
and 15 dB, and the intensities were provided electronically
by the Bigshot™ LED Ganzfeld stimulator. Ten waveforms
at flash intensities of −30, −20, and −10 dB, and five wave-
forms at 0, 5, 10, and 15 dB were recorded. The values from
each intensity were averaged in EM for Windows software
(Ver. 9.0.0, LKC Technologies, Gaithersburg, MD) before
analysis. To prevent the loss of dark adaptation and
allow rod recovery between consecutive flashes, timing
between flash intensity delivery was varied from 2 s at
the two lower stimulus intensities (−30 and −20 dB) to
30 s at −10 dB and up to 60 s at the next four higher
stimulus intensities (0, 5, 10, and 15 dB). The a wave
was measured from the pre-stimulus baseline to the nadir
of the initial corneal negative deflection; b wave was
measured from the nadir of the a wave to the apex of the
corneal positive wave and not up to the apex of oscillating
potentials, which can exceed the b wave apex (Fig. 5d).
Statistical analysis
All bar graphs represent mean ± SEM. Statistical ana-
lysis was performed using Student’s t test or one-way
ANOVA with a Bonferroni correction where appropri-
ate. p values < 0.05 were considered statistically signifi-
cant. Statistical analyses were performed using Statplus
(Analystsoft Inc, Walnut, CA).
Results
MMF upregulates the expression of antioxidant genes in
the retina via an Nrf2-dependent pathway
Fumaric acid esters, including MMF, induce upregulation
of antioxidant Nrf2 target genes in vitro [9] and exert neu-
roprotective effects in vivo [8]. In order to test if MMF
induces mRNA expression of antioxidative enzymes
[26-28] that are known to be targets of Nrf2 transcrip-
tional activation in retinal tissue, MMF was adminis-
tered daily via i.p. injections at a dose of 50 mg/kg
beginning 2 days before I/R injury until sacrificed. As
demonstrated in Fig. 1, MMF significantly increased
Nrf2 target gene expression in I/R retinas in WT mice.
Importantly, MMF did not increase the expression of
these target genes in Nrf2 KO mice, confirming that
this MMF effect was Nrf2-specific.
MMF treatment suppresses inflammatory gene expression
in the retina following ischemia-reperfusion
The absence of oxygen by prolonged ischemia creates a
condition in which the restoration of oxygen levels by
Fig. 1 MMF-treated mice exhibit significantly increased Nrf2 target gene expression in I/R retinas in wild-type, but not Nrf2 knockout, mice.
qRT-PCR analysis of Nrf2 target genes was performed on retinas harvested 7 days after reperfusion. n = 5-6 mice/group
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reperfusion results in a surge in the generation of re-
active oxygen species, leading to inflammation [29].
DMF and MMF have been demonstrated to suppress
inflammatory cytokine production in the CNS and sys-
temic settings [30]. IL-1β, CCL2, and ICAM-1 are classical
inflammatory genes that are known to be significantly in-
creased in I/R [31–33]. CCL2, in particular, is involved in
the inflammatory responses via recruitment of monocytes,
memory T cells, and dendritic cells to sites of injury [34–
37]. In addition, CCL2 as well as CCL7 and CCL12 is the
ligand for the CCR2 receptor, which is known to play an
important role in inflammatory diseases of the CNS [38,
39]. As shown in Fig. 2, MMF treatment significantly
suppressed I/R-induced upregulation of these inflam-
matory mediators at 48 h after reperfusion in wild-type,
but not Nrf2 knockout, mice, implicating that MMF ex-
erts anti-inflammatory effects in the retina in an Nrf2-
dependent manner.
MMF treatment mitigates Müller cell gliosis induced by
ischemia-reperfusion in the retina
Retinal ischemia results in reactive gliosis, which is
characterized by hypertrophy, proliferation, and upreg-
ulated expression of the intermediate filament, includ-
ing glial fibrillary acidic protein (GFAP), in Müller cells
[1, 40–42]. A recent in vitro study suggested that MMF
could prevent reactive gliosis by attenuating Müller cell
proliferation by decreasing folate uptake via the proton-
coupled folate transporter (PCFT) [42]. In order to test if
MMF can suppress reactive gliosis in Müller cells in vivo,
retinas were collected 7 days after I/R, and GFAP stain-
ing was performed. In mammalian retina under non-
pathological conditions, GFAP is constitutively expressed
in astrocytes but not in mature Müller cells [43]. As ob-
served in Fig. 3a, in control eyes without I/R injury, GFAP
immunolabeling was confined to the astrocytes in the gan-
glion cell layer. With I/R injury, however, GFAP expres-
sion was significantly (p = 0.0003) upregulated in Müller
cells (Fig. 3a, b). MMF treatment significantly (p = 0.017)
mitigated I/R-induced GFAP expression in the retina as
compared with vehicle treatment in the wild-type mice
(Fig. 3b). Notably, positive GFAP immunofluorescence
spanned all retinal layers from the inner limiting membrane
(ILM) to the outer nuclear layer (ONL) in vehicle-treated
wild-type I/R eyes, whereas GFAP immunofluorescence
was seldom observed in the ONL in MMF-treated eyes.
In Nrf2 KO mice, the I/R-induced GFAP upregulation
was significantly (p = 0.0014) higher as compared with
wild-type I/R eyes (Fig. 3b), suggesting that Nrf2 KO
mice may be more susceptible to Müller cell gliosis
than wild-type mice. As expected, MMF treatment of
Nrf2 KO mice did not mitigate the I/R-induced GFAP
upregulation; GFAP immunofluorescence spanned all ret-
inal layers regardless of the MMF treatments, implying
that the mitigation of GFAP upregulation by MMF is me-
diated through Nrf2 pathways (Fig. 3a, b).
MMF treatment protects retinal ganglion cells from
ischemia-reperfusion-induced cell death in
an Nrf2-dependent manner
Next, in order to test if the anti-inflammatory effects of
MMF are translated into neuronal protection after I/R
injury, neuronal cell survival in the ganglion cell layer
(GCL) was evaluated at 7 days after I/R by retinal flat-
mount analysis with NeuN staining [25, 44] (Fig. 4a, c).
Daily i.p. injection of MMF significantly (p = 0.0005) in-
creased ganglion cell survival in I/R eyes (33 % cell loss
in the MMF-treated group vs. 80 % cell loss in the
vehicle-treated group) in wild-type mice (Fig. 4b). Import-
antly, MMF-mediated inhibition of neuronal cell loss in
the GCL was not observed in Nrf2 KO mice (Fig. 4d), in-
dicating that the neuroprotective effect of MMF treatment
is mediated by an Nrf2-dependent mechanism.
MMF inhibits ischemia-reperfusion-induced functional
impairment in the retina
In order to examine the functional changes associated
with I/R injury, scotopic ERG was recorded from both
WT and Nrf2 KO mice. At 7 days after I/R injury, wild-
type mice treated with vehicle showed significant reduc-
tion in b wave amplitude at all intensities in I/R eyes as
compared with contralateral non-I/R control eyes (top
and bottom graphs in Fig. 5e). Comparing vehicle- and
MMF-treated I/R eyes (bottom 2 graphs in Fig. 5e), daily
i.p. injections of MMF resulted in increased b wave amp-
litude as compared with vehicle-treated mice. Specific-
ally, MMF treatment resulted in significant increases in
b wave amplitude at intensities of −10 dB (p = 0.021) and
15 dB (p = 0.049) (bottom 2 graphs in Fig. 5e). As antici-
pated, in Nrf2 KO mice, MMF treatments did not in-
crease b wave amplitude in I/R eyes (bottom 2 graphs in
Fig. 5f ). There was a non-significant trend toward an im-
proved a wave amplitude at higher flash intensities of 5,
10, and 15 dB in wild-type mice after MMF treatment
(Fig. 5g); however, such a trend was not present in Nrf2
KO mice (Fig. 5h).
Discussion
Recently, fumaric acid esters, specifically DMF and MMF,
collectively denoted here as FAEs, have gained consider-
able attention for their neuroprotective effects in CNS tis-
sues and enhanced survival of various CNS cell types in
vitro [8–11, 13]. Although their exact mode of action is
not known, the neuroprotective effects of FAEs are
thought to be mediated by activation of the Nrf2 pathway
[8, 9, 13]. Despite being an extension of the CNS, limited
information is available on the therapeutic effects of FAEs
on the retina. There have been a few in vitro studies
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Fig. 2 MMF treatment significantly suppresses inflammatory gene expression following I/R in wild-type, but not Nrf2 knockout, mice. qRT-PCR
analysis of inflammatory mediators was performed on retinas harvested 48 h after reperfusion. n = 9-10 mice/group
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examining the effects of MMF in Müller [42] and retinal
pigment epithelial [45, 46] cells, which suggest that the
FAEs may have therapeutic potential in retinal pathology.
In this study, we demonstrated using Nrf2 KO mice
that FAEs have beneficial effects in vivo on retinal in-
flammation and neuroprotection in an Nrf2-dependent
fashion. Strikingly, there have been only a few in vivo
studies that have utilized Nrf2 KO mice to implicate Nrf2
as the critical mechanism of FAEs action [8, 47, 48].
Notably, it has been shown in wild-type but not Nrf2
KO mice that DMF significantly increases axon/myelin
preservation with reduction in astrocyte activation in a
model of experimental autoimmune encephalomyelitis
[8], reduces the size of myocardial infarction in a cor-
onary artery ligation (myocardial I/R) model [47], and
improves neurological performance in the model of in-
tracerebral hemorrhage [48]. However, to our knowledge,
this is the first in vivo study showing that the effects of
FAEs on neuronal cell survival and inflammatory gene
expression are mediated by an Nrf2-dependent pathway.
Currently, there are no clinically approved neuroprotec-
tive drugs for acute and chronic retinal diseases. There-
fore, this study highlights FAEs as a promising retinal
therapy especially in light of recent FDA approval of DMF
for the treatment of multiple sclerosis.
In order to prove that the MMF activates the Nrf2 path-
way in the retina, we looked at Nrf2 target gene expres-
sion after MMF treatment and demonstrated that MMF
indeed upregulates the expression of Nrf2-responsive anti-
oxidative genes in the retina (Fig. 1). In agreement with
the upregulation of antioxidative genes, we found signifi-
cant reduction in inflammatory gene expression after I/R
injury in MMF-treated mice (Fig. 2). Importantly, both of
these effects were observed in wild-type but not in Nrf2
KO mice, emphasizing the Nrf2 dependence of these
beneficial effects of MMF.
Glial functions are altered during pathological pro-
cesses in the nervous system [49]. Müller cells are the
Fig. 3 MMF treatment significantly reduces retinal Müller cell gliosis associated with I/R injury at day 7. In control eyes, GFAP immunolabeling was mainly
present on the ILM (asterisk) (a). In wild-type I/R eyes treated with vehicle, the immunolabeling was significantly (p< 0.001) increased (b) when compared
with control eyes and extended almost throughout the entire retina to the ONL in the Müller cell processes (a). With MMF injection, the immunolabeling
was significantly (p< 0.05) reduced (b) and mainly extended to the OPL and only a small amount of GFAP immunolabeling was observed in the ONL
(a). In Nrf2 KO mice, both vehicle- and MMF-treatment showed extensive GFAP immunofluorescence throughout all retina layers to the ONL (a). I/R-in-
duced Muller cell gliosis was significantly (p< 0.01) higher in Nrf2 KO mice when compared with wild-type mice (b). n= 4-7 mice/group. ILM inner limiting
membrane, GCL ganglion cell layer, IPL inner plexiform layer, INL inner nuclear layer, OPL outer plexiform layer, ONL outer nuclear layer
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principle glial cells in the neural retina, and they
undergo reactive gliosis after acute injury or chronic
neuronal stress [50, 51]. We have previously shown that
Nrf2 is strongly expressed in both the human and
mouse retinas, especially in Müller cells [52], suggest-
ing that pharmacological activation of the Nrf2 pathway
in the retina may have a direct impact on Müller cells.
Our study showed that the reactive Müller cell gliosis
measured by GFAP staining was significantly decreased
with MMF treatment (Fig. 3). Interestingly, the extent
of Müller cell gliosis in vehicle-treated eyes spanned
the entire retina from the inner limiting membrane to
the outer nuclear layer, whereas a much smaller degree
of gliosis in MMF-treated eyes was mostly limited to
the inner retina in the inner plexiform layer and the
inner nuclear layer, a pattern very similar to previously
reported studies in which oral delivery of antioxidant
saffron was employed with retinal stress [53, 54]. This
could be due to the fact that the inner and outer retinas
demonstrate differential sensitivities to ischemic insult
[55, 56]. Because the pressure-induced I/R injury causes
a more severe damage to the inner retina, some of the
MMFs delivered systemically via intraperitoneal injec-
tion might have leaked through the damaged central
retinal vessels, making the delivery of drug less effective
to the inner retina, while the drug was more effectively
delivered to the outer retina via choroidal circulation,
which was not affected as strongly by I/R. Nonetheless,
I/R eyes treated with MMF showed an overall decrease
in reactive Müller cell gliosis when compared with ve-
hicle-treated animals, demonstrating strong neuroprotec-
tive effects of MMF in the retina. Contrary to wild-type
mice, Müller cell gliosis in Nrf2 KO mice showed no ef-
fects from MMF treatment; the gliosis spanned all retinal
layers in both MMF- and vehicle-treated groups, implicat-
ing that MMF-mediated suppression of Müller cell gliosis
is Nrf2-dependent. Because major retinal diseases, in-
cluding macular degeneration, retinitis pigmentosa, and
diabetic retinopathy, are associated with reactive Müller
cell gliosis [51], the activation of the Nrf2 pathway by
MMF could have a wide implication for the treatment
of retinal pathologies.
The neuroprotective effects of MMF in the retina were
highlighted by both the significant reduction of neuronal
Fig. 4 MMF treatment protects retinal ganglion cells from I/R-induced cell death in an Nrf2-dependent manner. Representative anti-NeuN stained
retinal flat-mount images from WT (a) and KO (c) mice are shown. MMF significantly (p < 0.001) inhibits neuronal cell loss in GCL at 7 days after I/R in
WT (b), but not KO (d), mice. n = 4-6 mice/group
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Fig. 5 (See legend on next page.)
Cho et al. Journal of Neuroinflammation  (2015) 12:239 Page 9 of 12
cell death in the ganglion cell layer (Fig. 4) and the recovery
of retinal function (Fig. 5). Since ERG b wave amplitude is a
particularly sensitive index of retinal ischemia [57] and
Müller cells are extensively involved in the generation of b
wave [58], we first looked at the b wave of the ERG to see if
the MMF-mediated reduction of Müller cell gliosis in I/R
eyes is associated with b wave recovery. In accordance with
our results from the Müller cell gliosis, we found that the b
wave was significantly depressed by the I/R injury and was
partially but significantly rescued by the MMF treatment at
multiple flash intensities. Although not statistically signifi-
cant as the b wave recovery, the a wave recovery was also
present with the MMF treatment. Taken together, these re-
sults imply that the neuroprotective effects of MMF span
all retinal layers, since the b wave and a wave reflect the
health of neurons in inner and outer layers of the retina,
respectively.
In this study, we included the inflammatory gene analyses
in addition to the neuroprotective endpoints which were
the focus of our study. Although we find these gene studies
to be insightful as they indicate that MMF also influences
the inflammatory milieu in I/R in an Nrf2-dependent man-
ner, a detailed characterization of response of specific in-
flammatory cell types will be helpful to gain a further
understanding of MMF’s anti-inflammatory effects.
We used MMF because it is the main metabolite that
exerts biological effects in vivo after ingestion of DMF [14,
15]. However, recent in vitro studies showed that there are
differential effects between DMF and MMF [9, 12, 59].
DMF was shown to be more potent than MMF in the in-
duction of Nrf2 activation in human astrocytes [9] and up-
regulation of intracellular GSH from oxidative glutamate
toxicity in mouse hippocampal cells [12]. In addition,
there is a growing evidence that not all DMF pharmaco-
logical effects are conveyed by MMF and that DMF may
have unique pharmacological properties and thus should
not just be considered as a prodrug of MMF [60, 61].
Therefore, further studies using DMF may provide a dee-
per insight into the action of FAEs in retinal protection.
Conclusions
Based on the results from concurrent experiments per-
formed in Nrf2 KO mice, we demonstrated that MMF-
mediated neuroprotective effects in the retina observed
in wild-type mice after I/R injury are indeed Nrf2-
dependent. Nrf2 has been known to play a protective
role in multiple disease settings [62], and we have previ-
ously shown that pharmacological targeting of Nrf2
using synthetic triterpenoids for retinal protection could
be a very promising strategy [2, 44]. There are multiple
agents that are known to target the Nrf2 pathway, in-
cluding sulforaphane, VEDA, and synthetic triterpenoids
among others. However, these drugs are still in early
stages of preclinical or clinical trials [62] or lack human
safety data. Therefore, FAEs could be a readily available
Nrf2-targeting drug for neuroprotection in the setting of
retinal I/R injury or in other conditions for which no
treatment options are presently available.
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Fig. 5 MMF treatment improves I/R-induced functional impairment in the retina in an Nrf2-dependent manner. An intensity series of dark-adapted
flash ERG traces from a representative non-I/R eye (a), and representative traces from I/R eyes with or without MMF treatment to a stimulus flash of
15 dB in wild-type (b) and KO (c) mice are shown. An illustration depicting measurements of a and b wave amplitudes are shown (d). Retinal
I/R injury significantly reduces b wave (e and f) and a wave (g and h) amplitudes in both wild-type and KO mice at day 7. With MMF treatment, b wave
amplitudes in I/R eyes show significant increases at −10 and 15 dB (e), whereas MMF shows no treatment effect in Nrf2 knockout mice (f). A
non-significant trend toward improved a wave amplitude at higher flash intensities of 5, 10, and 15 dB in wild-type mice after MMF treatment
(g), whereas no such trend was present in Nrf2 knockout mice (h). *p < 0.05, vehicle I/R compared with MMF I/R; ^p < 0.05, #p < 0.005, No I/R
control compared with vehicle I/R. n = 7-10 mice/group
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